Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
Lymphoma, Non-Hodgkin
BIOLOGICAL: Cytokine-induced killer cells (CIK)
Progression-Free-Survival (PFS), 1 month
Overall Survival (OS), 1 month
Lactic Dehydrogenase (LDH), 1 month
Autologous cytokine-induced killer (CIK) cells transfusion(\>2\*10\^9 cells count) within 2 weeks after regular chemotherapy every 3 months.